Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1

Hofbauer, Lorenz C., Heufelder, Armin E. · 2000 · The Journal of Clinical Endocrinology & Metabolism

Abstract

BONE IS permanently turned over by the balanced and coordinated action of bone-resorbing osteoclasts and bone-forming osteoblasts, resulting in continuous renewal, functional response to external and internal stimuli, and structural integrity (1–3). Inappropriate bone resorption caused by enhanced osteoclast formation and activity has been previously implicated in the pathogenesis of many metabolic bone diseases. Strategies to inhibit bone resorption have emerged as potent and promising tools for the prevention and treatment of bone and mineral disorders (1–3). The recent discovery and characterization of a novel cytokine system, the tumor necrosis factor (TNF) ligand family member, receptor activator of nuclear factor-κB ligand (RANKL/OPGL/ODF/TRANCE) (4–7);2 its receptor, receptor activator of nuclear factorκ B (RANK/ODAR) (7); and its soluble (decoy) receptor, osteoprotegerin (OPG/OCIF/TR1) (8–11), has established a novel paradigm of osteoclast biology: RANKL, RANK, and OPG constitute the three essential regulatory components of osteoclast formation, fusion, survival, activation, and apoptosis (12–14). This article3 reviews the molecular aspects of this novel cytokine system and its regulation and modulation by various osteotropic agents. Moreover, we summarize the implications of this cytokine system on the pathogenesis of various bone diseases and discuss the therapeutic potential of OPG in the clinical setting. The TNF ligand family member, osteoprotegerin ligand (OPGL)/osteoclast differentiation factor (ODF) was discovered in 1998 by two groups (4, 5) as the cognate ligand for OPG/osteoclastogenesis inhibitory factor (OCIF) (8, 9). This factor had been identified by the same two groups the year before and was shown to be identical to TNF-related activation-induced cytokine (TRANCE) (6) and receptor activator of nuclear factor-κB ligand (RANKL) (7). RANKL will be the preferred term according to a consensus nomenclature (12). RANKL is a cell-bound polypeptide of 317 amino acids (4, 5) that is cleaved by a protease, TNFα-converting enzyme-like protease (TACE) (15), at position 140 or 145, respectively, to give rise to a shorter soluble ectodomain variant of similar activity (4, 15). The major sources of RANKL production in the bone/bone marrow microenvironment are bone marrow stromal cells, osteoblasts, chondrocytes, mesenchymal cells of the periosteum, osteoclasts, endothelial cells, and T cells (4–7, 16). Detailed analyses of its extraskeletal tissue distribution revealed RANKL messenger ribonucleic acid (mRNA) and protein production in brain, heart, kidney, skeletal muscle, and skin (16). Of note, RANKL production is highest in undifferentiated stromal cells and is greatly reduced once these multipotential mesenchymal cells become terminally committed to the osteoblastic phenotype (17–19). Interestingly, the RANKL gene promoter structure contains both vitamin D and glucocorticoid response elements as well as a binding site for the essential osteoblastic transcription factor, cbfa-1 (20–22). In a series of in vitro experiments, RANKL was consistently shown to stimulate the differentiation, survival, and fusion of osteoclastic precursor cells, to activate mature osteoclasts, and to prolong their life span by inhibiting apoptosis (4, 5, 23–27), thus expanding the pool of active osteoclasts capable of forming resorption lacunae (Fig. 1). In the presence of permissive levels of macrophage colony-stimulating factor (M-CSF), RANKL is both sufficient and necessary for all steps of osteoclast development (28) (Fig. 1). Of note, other factors, such as transforming growth factor-β and PGE2, may cooperate and synergize with RANKL (29, 30), although the precise roles of these factors in osteoclast biology are not well defined. Regulation of osteoclast functions by RANKL, OPG, and RANK. Osteoblastic cells express a cell-bound and a soluble form of RANKL as well as the soluble neutralizing receptor, OPG. RANKL and OPG have opposite effects on osteoclast biology. 1) Multipotential macrophagic lineage cells are stimulated by M-CSF, which binds to its receptor c-fms to proliferate and to become osteoclast precursor cells. 2) Under permissive levels of M-CSF, binding of osteoblast-derived RANKL to the receptor RANK induces differentiation of osteoclast precursors to prefusion osteoclasts. OPG blocks this effect by neutralizing RANKL. 3) Survival and fusion are stimulated by RANKL, a process that yields multinucleated osteoclasts and is modulated by cytokines such as IL-1, TNFα, and IL-6 and is inhibited by OPG. 4) Osteoclasts are activated by RANKL (as well as IL-1, TNFα, and IL-6) and become capable of resorbing bone. This is blocked by OPG. 5) Mature osteoclasts undergo apoptosis, which is induced by OPG and prevented by RANKL. Regulation of osteoclast functions by RANKL, OPG, and RANK. Osteoblastic cells express a cell-bound and a soluble form of RANKL as well as the soluble neutralizing receptor, OPG. RANKL and OPG

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jcem.85.7.6702

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 169

Metadata

Authors
Hofbauer, L. C., & Heufelder, A. E.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2000-07
Volume
85
Issue
7
Pages
2355-2363
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2155352301
Cited by
169
References
26
FWCI
4.06
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1. https://app.cochat.ai/papers/10.1210/jcem.85.7.6702
The paper
Hofbauer, L. C., & Heufelder, A. E. (2000). The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jcem.85.7.6702

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.